$57.88
0.45% day before yesterday
Nasdaq, May 30, 10:00 pm CET
ISIN
US46266A1097
Symbol
IRMD

iRadimed Corp Stock price

$57.88
+5.47 10.44% 1M
+4.05 7.51% 6M
+2.88 5.24% YTD
+15.76 37.42% 1Y
+26.00 81.54% 3Y
+36.48 170.42% 5Y
+39.63 217.12% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.26 0.45%
ISIN
US46266A1097
Symbol
IRMD
Sector

Key metrics

Market capitalization $735.95m
Enterprise Value $685.62m
P/E (TTM) P/E ratio 37.34
EV/FCF (TTM) EV/FCF 49.75
EV/Sales (TTM) EV/Sales 9.12
P/S ratio (TTM) P/S ratio 9.79
P/B ratio (TTM) P/B ratio 8.17
Dividend yield 0.26%
Last dividend (FY23) $1.67
Revenue growth (TTM) Revenue growth 11.04%
Revenue (TTM) Revenue $75.15m
EBIT (operating result TTM) EBIT $22.65m
Free Cash Flow (TTM) Free Cash Flow $13.78m
Cash position $50.33m
EPS (TTM) EPS $1.55
P/E forward 36.40
P/S forward 9.27
EV/Sales forward 8.63
Short interest 2.45%
Show more

Is iRadimed Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

iRadimed Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a iRadimed Corp forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a iRadimed Corp forecast:

Buy
100%

Financial data from iRadimed Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
75 75
11% 11%
100%
- Direct Costs 17 17
9% 9%
23%
58 58
12% 12%
77%
- Selling and Administrative Expenses 33 33
29% 29%
43%
- Research and Development Expense 2.63 2.63
55% 55%
3%
23 23
9% 9%
31%
- Depreciation and Amortization 0.79 0.79
2% 2%
1%
EBIT (Operating Income) EBIT 23 23
9% 9%
30%
Net Profit 20 20
10% 10%
26%

In millions USD.

Don't miss a Thing! We will send you all news about iRadimed Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

iRadimed Corp Stock News

Neutral
GlobeNewsWire
3 days ago
WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position a...
Neutral
Seeking Alpha
27 days ago
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2025 Earnings Conference Call May 5, 2025 9:00 AM ET Company Participants Roger Susi - Founder, President & CEO John Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Welcome to the IRADIMED Corporation First Quarter of 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Neutral
GlobeNewsWire
27 days ago
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024. Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, re...
More iRadimed Corp News

Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices and accessories and services. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Head office United States
CEO Roger Susi
Employees 160
Founded 1992
Website www.iradimed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today